Company / R&D per Share
Seres Therapeutics, Inc. R&D per Share History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$13.59
FY2025
5-year range
$0.88 / $13.59
FY2021-FY2025
Trend
+1099.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share changed +1100% YoY in FY2025, a notable deviation from the 9-year average annual change of +151%.
Based on SEC 10-K filings.
13.59 in FY2025 with a 10-year CAGR of +34.6%.
Improved from $0.99 to $13.59 over the past 3 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +139.8%
- 5-Year CAGR
- +58.3%
- 10-Year CAGR
- +34.6%
Key checks
Key Insights
- Seres Therapeutics, Inc.'s r&d per share has grown for 3 consecutive years.
- In FY2025, r&d per share increased 1099.8% year-over-year.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.59 | +1099.8% |
| FY2023 | $1.13 | +15.0% |
| FY2022 | $0.99 | +12.5% |
| FY2021 | $0.88 | -35.9% |
| FY2020 | $1.37 | -37.4% |
| FY2019 | $2.19 | +8.1% |
| FY2018 | $2.02 | +114.1% |
| FY2017 | $0.94 | +244.2% |
| FY2016 | $0.27 | -60.7% |
| FY2015 | $0.70 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026